Mosaic ImmunoEngineering(CPMV)
$0.060.00 (0.00%)
CPMV
Mosaic ImmunoEngineering financials statements
$0.06
At close:0.00 (0.00%)
Mosaic ImmunoEngineering (CPMV) Ratios
28 Followers
Mosaic ImmunoEngineering Ratios
CPMV's free cash flow for Q2 2026 was $-46.00. For the 2026 fiscal year, CPMV's free cash flow was increased by $0.00 and operating cash flow was $-46.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 22 | Dec 21 | May 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.03 | 0.07 | 0.12 | 7.73 |
| Quick Ratio | 0.00 | 0.03 | 0.07 | 0.12 | 6.97 |
| Cash Ratio | 0.00 | 0.02 | 0.06 | 0.10 | 3.45 |
| Solvency Ratio | -0.09 | -0.01 | -0.40 | -1.15 | -3.50 |
| Operating Cash Flow Ratio | -0.02 | -0.04 | -0.18 | -0.29 | -3.33 |
| Short-Term Operating Cash Flow Coverage | -0.56 | -1.21 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -7.48M | $ -6.79M | $ -4.88M | $ -2.80M | $ 1.54M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 83.79 | 11.25 | 4.70 | 2.73 | 0.00 |
| Debt-to-Equity Ratio | -0.22 | -0.23 | -0.25 | -0.26 | 0.00 |
| Debt-to-Capital Ratio | -0.29 | -0.31 | -0.34 | -0.36 | 0.00 |
| Long-Term Debt-to-Capital Ratio | -0.24 | -0.26 | -0.34 | -0.36 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.02 | -0.05 | -0.10 | 1.13 |
| Debt Service Coverage Ratio | -2.18 | -2.99 | -32.79 | -116.32 | -11.71 |
| Interest Coverage Ratio | -7.39 | -10.93 | -37.68 | -121.55 | -11.69 |
| Debt to Market Cap | 0.74 | 0.32 | 0.17 | 0.11 | 0.00 |
| Interest Debt Per Share | 0.24 | 0.24 | 0.18 | 0.11 | 0.08 |
| Net Debt to EBITDA | -2.70 | -1.76 | -0.44 | -0.15 | 1.07 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.35% | 100.26% | 100.10% | 100.07% | 100.20% |
| EBT Per EBIT | 111.25% | 104.54% | 90.52% | 100.57% | 108.56% |
| Return on Assets (ROA) | -3459.64% | -651.07% | -911.24% | -1367.18% | -41.48% |
| Return on Equity (ROE) | 9.20% | 13.58% | 48.74% | 131.63% | -47.06% |
| Return on Capital Employed (ROCE) | 10.25% | 16.30% | 71.86% | 177.40% | -43.27% |
| Return on Invested Capital (ROIC) | 10.60% | 16.93% | 71.86% | 177.40% | -43.27% |
| Return on Tangible Assets | -3459.64% | -651.07% | -911.24% | -1367.18% | -41.48% |
| Earnings Yield | -30.56% | -18.54% | -33.24% | -53.81% | -114.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.03 | -0.10 | -0.10 | -0.95 |
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.10 | -0.10 | -0.95 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.07 | -0.15 | -0.56 | -0.92 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -4.95% | -4.85% | -9.63% | -9.92% | -109.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.27 | -5.39 | -3.01 | -1.86 | -0.87 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.30 | -0.73 | -1.47 | -2.45 | 0.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -20.20 | -20.62 | -10.38 | -10.08 | -0.92 |
| Price-to-Operating Cash Flow Ratio | -20.20 | -20.62 | -10.38 | -10.08 | -0.92 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | 0.00 | 0.08 | 0.00 | 0.00 |
| Enterprise Value Multiple | -6.35 | -7.70 | -3.58 | -2.10 | 0.12 |
| Enterprise Value | 3.91M | 6.45M | 8.17M | 7.36M | -89.63K |
| EV to EBITDA | -6.35 | -7.70 | -3.58 | -2.10 | 0.12 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -35.12 | -26.75 | -11.84 | -10.83 | 0.12 |
| EV to Operating Cash Flow | -35.12 | -26.75 | -11.84 | -10.83 | 0.12 |
| Tangible Book Value Per Share | -1.03 | -0.96 | -0.68 | -0.42 | 2.13 |
| Shareholders’ Equity Per Share | -1.03 | -0.96 | -0.68 | -0.42 | 2.13 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.10 | -0.13 | -0.33 | -0.55 | -1.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.11 | 1.10 | 0.91 | 1.01 | 1.09 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.16 | 0.26 | 0.29 | 0.18 | 0.95 |
Currency in USD
